Literature DB >> 19052927

Patient rationale in selecting androgen deprivation (PRISAD): do we give patients what they want?

Eric Chung1, Hunter Watt, Amanda Glasgow, Tim Skyring.   

Abstract

To assess patient rationale in selecting androgen deprivation, structured telephone interviews were conducted on consecutive patients on androgen deprivation over a 17-year period. The majority of these patients have stable disease that require long-term follow-up with 6-monthly PSA estimations. Synchronous PSA check with depot injections are preferred by majority of patients and longer intervals between the depot administrations are preferable due to perceived less needle pain. This study highlights for the first time patients' preferences for synchronous PSA check with their depot injections and a longer interval between the depot administrations due to perceived less needle pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052927     DOI: 10.1007/s12032-008-9139-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  13 in total

Review 1.  Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.

Authors:  Claude Schulman; Antonio Alcaraz; Richard Berges; Francesco Montorsi; Pierre Teillac; Bertrand Tombal
Journal:  BJU Int       Date:  2007-07       Impact factor: 5.588

2.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

3.  Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.

Authors:  Norman R Zinner; Mohamed Bidair; Arthur Centeno; Kevin Tomera
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

4.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.

Authors:  D McLeod; N Zinner; K Tomera; D Gleason; N Fotheringham; M Campion; M B Garnick
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

5.  Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Authors:  J Seidenfeld; D J Samson; V Hasselblad; N Aronson; P C Albertsen; C L Bennett; T J Wilt
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

Review 6.  Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.

Authors:  P-A Abrahamsson; J Anderson; L Boccon-Gibod; C Schulman; U E Studer; M Wirth
Journal:  Eur Urol       Date:  2005-10-11       Impact factor: 20.096

Review 7.  EAU guidelines on prostate cancer.

Authors:  G Aus; C C Abbou; M Bolla; A Heidenreich; H-P Schmid; H van Poppel; J Wolff; F Zattoni
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

8.  Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.

Authors:  M F Sarosdy; P F Schellhammer; M S Soloway; N J Vogelzang; E D Crawford; J Presti; G W Chodak; P Mitchell; L Porter
Journal:  BJU Int       Date:  1999-05       Impact factor: 5.588

9.  A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.

Authors:  E David Crawford; Oliver Sartor; Franklin Chu; Ramon Perez; Gary Karlin; J Steve Garrett
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

10.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.